First Citizens BancShares FCNCA has outperformed the market over the past 10 years by 11.17% on an annualized basis producing an average annual return of 21.97%. Currently, First Citizens BancShares has a market capitalization of $25.44 billion.

Financial giants have made a conspicuous bearish move on ZIM Integrated Shipping. Our analysis of options history for ZIM Integrated Shipping ZIM revealed 25 unusual trades. Delving into the details, we found 36% of traders were bullish, while 64% showed bearish tendencies.

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories ABT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

Whales with a lot of money to spend have taken a noticeably bullish stance on Nutrien. Looking at options history for Nutrien NTR we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ...

TORONTO, March 25, 2025 /CNW/ - SiriusXM Canada and GRAMMY award-winning British folk rock band Mumford & Sons today announced the launch of an exclusive pop-up channel, Mumford & Sons Radio, ahead of the long-awaited release of the band's fifth studio album RUSHMERE.

Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics ...

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting ...

- FHD-909 ( LY4050784 ) advancing in an ongoing Phase 1 trial in SMARCA4 ( BRG1 ) mutated cancers, with non-small cell lung cancer ( NSCLC ) as the primary target population - Oral presentation on preclinical data for FHD-909 in combination with chemotherapy, pembrolizumab and KRAS ...

• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors • New preclinical data for IO170 add to growing body of evidence supporting ...